CLV for Nationally Manufactured Devices: Two Documents, Ten Working Days
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
For devices manufactured in Nicaragua, the certificate of free sale (CLV) is issued by DDM under Annex E to NTON 24001:2023. The application is filed on a working day by the regente sanitario of the manufacturing establishment, and it consists of two documents: the ROC payment receipt and the official application form in its current version, signed and sealed. Where the application meets the requirements, the certificate is issued within a maximum of ten working days. Where it does not, a record of rejection (Acta de Rechazo) is issued and a fresh filing is required. A NOTA adds a substantive condition: the sanitary registration of the product for which the CLV is sought must have at least six months of validity remaining.
- DDM issues the CLV for domestically manufactured devices (Chapter 5, Article 12).
- The applicant is the regente sanitario of the manufacturing establishment (Annex E, Article 1).
- Only two documents are required: the ROC receipt and the signed and sealed application form.
- The certificate is issued within ten working days at most (Annex E, Article 4).
- The registration must have at least six months of validity remaining (Annex E, Article 2, NOTA).
- A non-compliant filing produces an Acta de Rechazo and must be resubmitted (Annex E, Article 5).
2. Legal basis
The CLV procedure sits entirely in one place: Chapter 5, Article 12 of the standard refers to Annex E, and Annex E sets out the applicant, the documents, the timing and the consequence of a defective filing.
| Technical standard | NTON 24001:2023, Tecnología de la salud. Dispositivos médicos. Requisitos para el Registro Sanitario (La Gaceta No. 192, 21 October 2024) | Chapter 5, Article 12 | For devices manufactured in the country, DDM issues a CLV on application by the manufacturing establishment, following the procedure in Annex E |
| Technical standard | NTON 24001:2023 | Annex E (normative), Article 1 | The application is filed by the regente sanitario of the manufacturing establishment on a working day |
| Technical standard | NTON 24001:2023 | Annex E, Article 2 a and b | Two documents: the ROC receipt for the CLV item under RM 347-2023, and the official application form in its current version, signed and sealed by the regente sanitario |
| Technical standard | NTON 24001:2023 | Annex E, Article 2, NOTA | At the time the CLV is issued, the sanitary registration of the product must have at least six months of validity remaining |
| Technical standard | NTON 24001:2023 | Annex E, Article 4 | Where the requirements are met, the CLV is issued within a maximum of ten working days |
| Technical standard | NTON 24001:2023 | Annex E, Article 5 | Where they are not met, an Acta de Rechazo is issued and the regente sanitario must file again |
Chapter 5, Article 12 delegates the detail to Annex E rather than restating it in the body of the standard, and Annex E is marked as normative, so its content is binding rather than illustrative. The annex is short because the certificate rests on a registration that already exists: the applicant, the two documents and the two possible outcomes are the whole of the procedure.
3. Expert insights
Insight one: the issuing body is DDM, not the authority of the country of manufacture. This mirrors Chapter 6, item 7, under which the CLV for imported devices is issued by the competent authority of the country of origin or by a PAHO/WHO reference institution. The same certificate follows two different issuing routes depending on where the device is made, and the domestic route asks for only two documents.
Insight two: the six-month rule is a substantive threshold. The NOTA states «el registro sanitario del producto deberá encontrarse con una vigencia mínima de 6 meses». A product whose registration is close to expiry cannot obtain a CLV; it must be renewed first. The rule ties CLV scheduling to renewal scheduling.
Insight three: the applicant is the regente sanitario, not the registrador. Unlike product registration, which is filed by a registrador, the CLV runs through the establishment-side regente channel, consistent with the party that files sanitary licence applications (RA 0007/2025, Anexo I, Article 5 item a). In a single company these may be two different people.
Insight four: two documents makes this the leanest normative annex. Annex D on classification requires three items; Annex E requires two. That matches what the CLV is — a statement of status rather than a technical assessment.
Insight five: as with Annex D, a defective filing means starting again, not correcting. Article 5 states «debiendo el regente sanitario presentar un nuevo trámite». There is no correction window in this procedure, so the documents have to be right the first time.
Insight six: the text governs the procedure, not the use of the certificate. NTON does not say whether the domestic CLV serves export or domestic circulation, and this review makes no assumption either way. Where the intended use matters, it should be confirmed with DDM in writing.
4. Practical recommendations
- Route a domestic CLV through Annex E, named by the regente sanitario rather than the registrador.
- Before filing, check that the product’s registration has at least six months remaining (NOTA); renew first if it does not.
- Prepare exactly two documents: the ROC receipt for the CLV item under RM 347-2023 and the current application form, signed and sealed.
- Plan on a maximum of ten working days and hold a fallback for resubmission if the file is rejected.
- Tie CLV scheduling to renewal scheduling, renewing first where less than six months of registration validity remains.
- Where the intended use of the CLV is unclear, ask DDM in writing rather than assuming practice from other markets.
5. Verification checklist
- □ The CLV application is filed in the name of the manufacturing establishment’s regente sanitario
- □ The remaining validity of the product registration has been checked as at least six months (Annex E, NOTA)
- □ Both documents are ready: the ROC receipt and the current application form, signed and sealed
- □ Scheduling allows a maximum of ten working days, with a resubmission plan if rejected
- □ CLV scheduling is tied to product renewal scheduling
- □ If the intended use of the CLV is unclear, DDM has been consulted in writing
Regulatory information verified as of 29 October 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us